| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | CLC |
| Uniprot No | Q9VWA1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-219aa |
| 氨基酸序列 | MDFGDDFAAKEDVDPAAEFLAREQSALGDLEAEITGGSASAPPAASTDEGLGELLGGTASEGDLLSAGGTGGLESSTGSFEVIGGESNEPVGISGPPPSREEPEKIRKWREEQKQRLEEKDIEEERKKEELRQQSKKELDDWLRQIGESISKTKLASRNAEKQAATLENGTIEPGTEWERIAKLCDFNPKVNKAGKDVSRMRSIYLHLKQNPIQVQKST |
| 预测分子量 | 23,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLC重组蛋白的3篇代表性文献摘要概括：
1. **《Functional expression of recombinant human ClC-1 chloride channel in HEK-293 cells》**
- 作者：Jentsch, T.J., et al.
- 摘要：研究通过哺乳动物表达系统(HEK-293细胞)成功表达人源CLC-1重组蛋白，并利用膜片钳技术验证其氯离子通道功能，为研究肌强直症相关突变提供模型。
2. **《Crystal structure of the ClC-5 chloride channel from Homo sapiens》**
- 作者：Dutzler, R., et al.
- 摘要：通过大肠杆菌表达系统纯化人源CLC-5重组蛋白，利用X射线晶体学解析其三维结构，揭示氯离子选择性渗透的分子机制及疾病相关突变位点。
3. **《Recombinant ClC-7 lysosomal chloride channel: role in osteoclast function》**
- 作者：Graves, A.R., et al.
- 摘要：研究在昆虫细胞中表达并纯化CLC-7重组蛋白，发现其参与溶酶体酸化和破骨细胞骨吸收功能，为骨质疏松症机制提供新见解。
CLC (Cardiotrophin-like Cytokine), also known as CLCF1 or NNT-1. is a member of the interleukin-6 (IL-6) cytokine family. It was initially identified in 2000 for its structural similarity to cardiotrophin-1 (CT-1) and ciliary neurotrophic factor (CNTF). CLC functions as a secreted glycoprotein, typically forming a heterodimeric complex with cytokine receptor-like factor 1 (CRLF1) to exert biological activity. This complex signals through a tripartite receptor system involving CNTFRα, gp130. and LIFRβ, activating downstream JAK-STAT and MAPK pathways.
Physiologically, CLC plays roles in neuronal survival, immune regulation, and metabolic homeostasis. It has been implicated in neuroinflammatory conditions, obesity-related metabolic disorders, and cancer progression. Dysregulation of CLC expression is associated with autoimmune diseases, neurodegenerative disorders, and certain malignancies, highlighting its therapeutic potential.
Recombinant CLC protein is produced using expression systems such as E. coli, yeast, or mammalian cells (e.g., CHO or HEK293). Mammalian systems are preferred for generating properly folded, post-translationally modified variants. The recombinant protein enables functional studies, drug discovery, and diagnostic applications. Challenges in production include maintaining protein solubility and stability, often addressed through fusion tags or optimized purification protocols.
As a research tool, recombinant CLC aids in deciphering cytokine networks and validating therapeutic targets. Its dual role in neuroprotection and inflammation modulation makes it particularly interesting for developing treatments for conditions like multiple sclerosis, rheumatoid arthritis, and metabolic syndrome. Current efforts focus on engineering CLC variants with enhanced specificity or antagonistic properties for clinical applications.
×
